<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404259</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 131</org_study_id>
    <nct_id>NCT02404259</nct_id>
  </id_info>
  <brief_title>PK TDF in Thai HIV-infected Children</brief_title>
  <official_title>Pharmacokinetics Study of Tenofovir in HIV-infected Thai Children Using Tenofovir-based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of TDF in Thai HIV-infected children
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected children who are currently on TDF-base once daily regimen will be enrolled into
      this study. PK visit will be performed at least 1 month after changing regimen to once daily
      regimen. Adherence 3 days before PK study will be confirmed using adherence questionnaire.
      100% of adherence is needed for PK study. If there is adherence problem on PK visit, PK study
      will be deferred to at least 3 days. On PK visit, blood drawn will be performed at 0, 2, 4,
      6, 8, 10, 12, 24 hr. after taking ARVs for PK study. Blood drawn for safety evaluation will
      be drawn at any time-point on the PK visit. There is no study drug in this study. All ARVs
      that patient taking will be according to patient's requirement, and physician judgment. ARVs
      dosage will follow the Thai national pediatric guideline. CBC, CD4, viral RNA, viral
      resistance, ALT, cholesterol, and triglyceride results can be from other visits within 4
      weeks window period.

      Statistical considerations Sample size calculations. There are no pharmacokinetic data in
      children. In adults, the mean (SD) AUC following administration of a 300mg Viread tablet in
      fasting state is 2.29 (0.69) microg.hr/mL. In patients taking lopinavir/ritonavir and
      atazanavir/ritonavir, the mean AUC of TDF is increased by 32% and 24% respectively. Efavirenz
      does not change the AUC of TDF. If the weight adjusted dose of TDF in children and
      adolescents achieves the same AUC as in adults and concomitant dosing with a protease
      inhibitor increases the TDF AUC by 30% but concomitant dosing with Efavirenz does not change
      the TDF AUC, then 20 treated with Efavirenz and 20 patients treated on a PI based regimen
      would provide 90% power to detect this difference at the 5% significance level.

      Statistical Analysis.

      Primary endpoints Pharmacokinetic parameters will be calculated based on individual plasma
      concentration vs time data, using noncompartmental methods. Data will be summarized overall
      and by whether the patient is taking a PI or an EFV-based regimen. Formal statistical
      comparisons of parameters will be made using ANOVA techniques or non-parametric equivalents
      as appropriate. Effect sizes and 95% confidence intervals will be given for all comparisons.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve (AUC) (pharmacokinetics of TDF)</measure>
    <time_frame>12 months</time_frame>
    <description>pharmacokinetics of TDF in children between the ages of 8-18 years</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>non-nucleoside reverse transcriptase inhibitor (NNRTI)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ritonavir-boosted protease inhibitor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>lopinavir/ritonavir atazanavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF (Tenofovir)</intervention_name>
    <arm_group_label>non-nucleoside reverse transcriptase inhibitor (NNRTI)</arm_group_label>
    <arm_group_label>ritonavir-boosted protease inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <arm_group_label>non-nucleoside reverse transcriptase inhibitor (NNRTI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir, atazanavir/ritonavir</intervention_name>
    <arm_group_label>ritonavir-boosted protease inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children between the ages of 8-18 years with documented HIV infection

          -  currently on TDF once daily regimen

          -  have signed the informed consent

        Exclusion Criteria:

          -  the child or care taker refuse to participate in the study

          -  severity of adverse events is more than grade 3 thirty days before participating in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanyawee Puthanakit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT and Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)'s website</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>TDF</keyword>
  <keyword>HIV-infected children</keyword>
  <keyword>Thai</keyword>
  <keyword>non-nucleoside reverse transcriptase inhibitor (NNRTI)</keyword>
  <keyword>ritonavir-boosted protease inhibitor (bPI)</keyword>
  <keyword>less than eighteen years old</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

